Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Extended Outcomes of Intravesical Valrubicin and Docetaxel as a Secondary Salvage Treatment for Recalcitrant High-risk Non–muscle-invasive Bladder Cancer

European Urology Focus(2025)10.1016/j.euf.2025.05.022Source: DataRank Database

Extended Outcomes of Intravesical Valrubicin and Docetaxel as a Secondary Salvage Treatment for Recalcitrant High-risk Non–muscle-invasive Bladder Cancer is a research paper published in European Urology Focus (2025). On theSindex it has a DataRank of 0. It has been cited 1 time.

N/A

0DataRank · unranked

Scored on demand from live citation data

1 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 2.07)OA: closedTopics (32)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (6)

Ryan L. Steinberg ORCID,Helen Y. Hougen ORCID,Sarah L. Mott ORCID,Vignesh T. Packiam ORCID,Michael A. O’Donnell ORCID

Live enrichment

PubMed:40579321 OpenAlex:https://openalex.org/W4411676335

National Institutes of Health

The John and Carol Walter Family Foundation

FWCI

2.07

Citation Percentile

0.9%

Citation Trend

2025

2026

closedLicense: https://www.elsevier.com/legal/tdmrep-license

publisherhttps://api.elsevier.com/content/article/PII:S240545692500152X?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S240545692500152X?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.euf.2025.05.022

repositoryhttps://pubmed.ncbi.nlm.nih.gov/40579321

Fields of Study

Bladder and Urothelial Cancer TreatmentsUrinary and Genital Oncology StudiesUrinary Bladder and Prostate Research

MeSH Terms

DocetaxelNon-Muscle Invasive Bladder NeoplasmsAdministration, IntravesicalAgedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsUrinary Bladder NeoplasmsDoxorubicinFemaleHumansMaleMiddle AgedNeoplasm InvasivenessNeoplasm Recurrence, LocalRetrospective StudiesSalvage TherapyTreatment Outcome

Keywords

MedicineDocetaxelBladder cancerSalvage therapyUrologyOncologyInternal medicineCancerSurgeryChemotherapyUrinary bladderUrinary Bladder Neoplasms

Sustainable Development Goals

SDG 0: Zero hunger

Extended Outcomes of Intravesical Valrubicin and Docetaxel as a Secondary Salvage Treatment for Recalcitrant High-risk Non–muscle-invasive Bladder Cancer

FAIR Checklist

Authors (6)

Funding (2 grants)

Impact

Open Access

Topics